Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Vaccines|February 24, 2024
Long-Term Clinical Safety of the Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: A Prospective, Multi-Country, Observational StudyAdeep Puri, Andrew J Pollard, Catherine Schmidt-Mutter, et al.
Frontiers in Global Women'S Health|December 20, 2024
Pregnancy and neonatal outcomes in Eastern Democratic Republic of the Congo: a systematic reviewKambale Kasonia, Hannah Brindle, Daniela Manno, et al.
Tropical Medicine & International Health : TM & IH|April 3, 2025
Regulator experiences of trials during Ebola epidemics in Sierra Leone, Guinea, and the Democratic Republic of the CongoKambale Kasonia, Frank Baiden, Frédéric Le Marcis, et al.
Emerging Infectious Diseases|February 24, 2022
Ebola Virus Glycoprotein IgG Seroprevalence in Community Previously Affected by Ebola, Sierra LeoneDaniela Manno, Philip Ayieko, David Ishola, et al.
Vaccine|November 19, 2023
Safety and immunogenicity of an Ad26.ZEBOV booster vaccine in Human Immunodeficiency Virus positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola: A single-arm, open-label Phase II clinical trial in Kenya and UgandaEdward Man-Lik Choi, Ggayi Abu-Baker Mustapher, Gloria Omosa-Manyonyi, et al.
Vaccines|August 26, 2023
The Effect of Previous Exposure to Malaria Infection and Clinical Malaria Episodes on the Immune Response to the Two-Dose Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine RegimenDaniela Manno, Catriona Patterson, Abdoulie Drammeh, et al.
The Lancet. Infectious Diseases|September 16, 2021
Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trialDavid Ishola, Daniela Manno, Muhammed O Afolabi, et al.
The Lancet. Infectious Diseases|October 23, 2022
Safety and immunogenicity of an Ad26.ZEBOV booster dose in children previously vaccinated with the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen: an open-label, non-randomised, phase 2 trialDaniela Manno, Agnes Bangura, Frank Baiden, et al.
The Lancet. Infectious Diseases|September 16, 2021
Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trialMuhammed O Afolabi, David Ishola, Daniela Manno, et al.
Vaccines|August 29, 2024
Delivery and Safety of a Two-Dose Preventive Ebola Virus Disease Vaccine in Pregnant and Non-Pregnant Participants during an Outbreak in the Democratic Republic of the CongoHugo Kavunga-Membo, Deborah Watson-Jones, Kambale Kasonia, et al.
Pageof 5